Cyprium Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2017-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.cypriumtx.com
Long Term Follow-up on Menkes Disease Patients
- Conditions
- Menkes Disease
- Interventions
- Drug: Long Term Follow-Up
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Cyprium Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04337684
- Locations
- 🇺🇸
Cyprium Study Team, New York, New York, United States
Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency
Phase 3
Completed
- Conditions
- Unexplained Copper DeficiencyMenkes DiseaseOccipital Horn Syndrome
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Cyprium Therapeutics, Inc.
- Target Recruit Count
- 93
- Registration Number
- NCT00811785
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath